Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.50 |
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.34 |
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | FBP1 | P09467 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | FLT1 | P17948 | 1/20 | 0.33 |
| ▸ | FLT4 | P35916 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25174364 | 1.00 | KMT2A (0.50) | KMT2AMEN1L3MBTL1CYP1A2CYP3A4 | |
| SCHEMBL25170458 | 0.85 | KMT2A (0.54) | KMT2AMEN1L3MBTL1CYP1A2CYP3A4 | |
| SCHEMBL30520708 | 0.85 | KMT2A (0.54) | KMT2AMEN1L3MBTL1CYP1A2CYP3A4 | |
| SCHEMBL30521401 | 0.83 | KMT2A (0.49) | KMT2AMEN1L3MBTL1CYP1A2CYP3A4 | |
| SCHEMBL31543931 | 0.83 | KMT2A (0.39) | KMT2AMEN1L3MBTL1CYP1A2CYP3A4 | |
| SCHEMBL25174444 | 0.83 | KMT2A (0.39) | KMT2AMEN1L3MBTL1CYP1A2CYP3A4 | |
| SCHEMBL16959204 | 0.81 | KMT2A (0.46) | KMT2AMEN1L3MBTL1CYP1A2CYP3A4 | |
| SCHEMBL25433979 | 0.80 | TMPRSS4 (0.39) | KMT2AMEN1L3MBTL1CYP1A2CYP3A4 | |
| SCHEMBL31220762 | 0.80 | TMPRSS4 (0.39) | KMT2AMEN1L3MBTL1CYP1A2CYP3A4 | |
| SCHEMBL26582862 | 0.77 | FFAR1 (0.41) | KMT2AMEN1ARCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4653053-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | Flare Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4426434-B1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS INC (US) | 2025-08-20 | — | — | EP | disclosed |
| US-20250186425-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS INC. | 2025-06-12 | — | — | US | disclosed |
| CN-119677720-A | PPARG inverse agonists and uses thereof | 弗拉雷治疗公司 | 2025-03-21 | — | — | CN | disclosed |
| US-20250084038-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS INC. | 2025-03-13 | — | — | US | disclosed |
| EP-4490147-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | Flare Therapeutics Inc. (US) | 2025-01-15 | — | — | EP | disclosed |
| CN-118984823-A | PPARG inverse agonists and uses thereof | 弗拉雷治疗公司 | 2024-11-19 | — | — | CN | disclosed |
| EP-4426434-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | Flare Therapeutics, Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| US-11820747-B2 | PPARG inverse agonists and uses thereof | FLARE THERAPEUTICS INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230331678-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS INC. | 2023-10-19 | — | — | US | disclosed |
| WO-2023172845-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS INC. (US) | 2023-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186425-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | PPARG, PPARA, PPARD | KMT2A 4230/4885MEN1 4646/4885L3MBTL1 4085/4885 |
| US-11820747-B2 | PPARG inverse agonists and uses thereof | PPARG, PPARA, PPARD | KMT2A 4163/4885MEN1 4630/4885L3MBTL1 4104/4885 |
| US-20250084038-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | PPARG, PPARA, PPARD | KMT2A 4163/4885MEN1 4630/4885L3MBTL1 4104/4885 |
| US-20230331678-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | PPARG, PPARA, PPARD | KMT2A 4163/4885MEN1 4630/4885L3MBTL1 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.